{"id":3290,"date":"2019-11-03T16:02:27","date_gmt":"2021-11-23T14:46:49","guid":{"rendered":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?p=3290"},"modified":"2021-11-23T15:46:52","modified_gmt":"2021-11-23T14:46:52","slug":"4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c","status":"publish","type":"post","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","title":{"rendered":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C"},"content":{"rendered":"

4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C<\/strong><\/p>\n

 <\/strong><\/p>\n

A notre connaissance, l’\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d’h\u00e9patite C chronique, en comparant les patients trait\u00e9s aux patients non trait\u00e9s, ind\u00e9pendamment du statut de r\u00e9ponse virologique soutenue, avec un contr\u00f4le minutieux des biais. Les analyses montrent que le traitement par AVD est associ\u00e9 \u00e0 une diminution rapide de la mortalit\u00e9 toutes causes confondues et de l’incidence du carcinome h\u00e9patocellulaire et que ces associations inverses sont plus fortes chez les patients atteints de cirrhose. Ces r\u00e9sultats ont \u00e9t\u00e9 publi\u00e9s dans la revue The Lancet en f\u00e9vrier 2019. Cette \u00e9tude a \u00e9t\u00e9 consid\u00e9r\u00e9e comme offrant des preuves substantielles que la gu\u00e9rison du VHC d\u00e9livr\u00e9e par des r\u00e9gimes d’antiviraux \u00e0 action directe tout oraux est associ\u00e9e \u00e0 des avantages cliniques et fournit les meilleures preuves \u00e0 ce jour pour soutenir les documents d’orientation qui recommandent un traitement antiviral \u00e0 action directe pour tous les patients atteints d’une infection chronique par le VHC. Enfin, ils apportent du cr\u00e9dit \u00e0 la possibilit\u00e9 d’atteindre les objectifs fix\u00e9s par l’OMS, non seulement d’\u00e9liminer le VHC mais aussi de r\u00e9duire consid\u00e9rablement ses complications.<\/p>\n

 <\/p>\n

Dans un travail ult\u00e9rieur, nous avons cherch\u00e9 \u00e0 savoir si les DAA pouvaient augmenter le risque \u00e0 court terme de d\u00e9velopper un carcinome h\u00e9patocellulaire tout en diminuant le risque \u00e0 long terme. Nous avons caract\u00e9ris\u00e9 l’effet variable dans le temps des AVDs sur le risque de survenue d’un CHC chez les patients atteints de cirrhose et d’infection par le VHC.). Dans l’ensemble, on a constat\u00e9 une diminution constante du risque de survenue d’un CHC (par rapport aux patients non trait\u00e9s) depuis le d\u00e9but du traitement. Cependant, le risque a augment\u00e9 chez les patients n’ayant pas de RVS.<\/p>\n

 <\/p>\n

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study<\/strong><\/p>\n

Carrat F & al.<\/p>\n

Lancet<\/em>. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016\/S0140-6736(18)32111-1. Epub 2019 Feb 11<\/p>\n

 <\/p>\n

The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C<\/strong>.<\/p>\n

Lusivika-Nzinga C & al.<\/p>\n

J Viral Hepat<\/em>. 2019 Aug 6. doi: 10.1111\/jvh.13186.<\/p>\n

 <\/p>\n

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.<\/strong><\/p>\n

Laurain A & al.<\/p>\n

BMC Infect Dis<\/em>. 2019 Apr 2;19(1):300. doi: 10.1186\/s12879-019-3923-5.<\/p>\n

 <\/p>\n

Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy.<\/strong><\/p>\n

Pronier C  & al.<\/p>\n

J Viral Hepat<\/em>. 2019 Jul 5. doi: 10.1111\/jvh.13171.<\/p>\n","protected":false},"excerpt":{"rendered":"

4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C   A notre connaissance, l’\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d’h\u00e9patite C chronique, en comparant les patients trait\u00e9s aux patients […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-3290","post","type-post","status-publish","format-standard","hentry","category-actualites"],"yoast_head":"\n4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER\" \/>\n<meta property=\"og:description\" content=\"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C   A notre connaissance, l’\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d’h\u00e9patite C chronique, en comparant les patients trait\u00e9s aux patients […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\" \/>\n<meta property=\"og:site_name\" content=\"ANRS CO22 HEPATHER\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-23T14:46:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-23T14:46:52+00:00\" \/>\n<meta name=\"author\" content=\"admin_fchau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_fchau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\"},\"author\":{\"name\":\"admin_fchau\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363\"},\"headline\":\"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C\",\"datePublished\":\"2021-11-23T14:46:49+00:00\",\"dateModified\":\"2021-11-23T14:46:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\"},\"wordCount\":481,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\",\"name\":\"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\"},\"datePublished\":\"2021-11-23T14:46:49+00:00\",\"dateModified\":\"2021-11-23T14:46:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"name\":\"ANRS CO22 HEPATHER\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\",\"name\":\"IPLESP UMRS 1136\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"width\":464,\"height\":175,\"caption\":\"IPLESP UMRS 1136\"},\"image\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363\",\"name\":\"admin_fchau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"caption\":\"admin_fchau\"},\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_fchau\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","og_locale":"fr_FR","og_type":"article","og_title":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER","og_description":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C   A notre connaissance, l’\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d’h\u00e9patite C chronique, en comparant les patients trait\u00e9s aux patients […]","og_url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","og_site_name":"ANRS CO22 HEPATHER","article_published_time":"2021-11-23T14:46:49+00:00","article_modified_time":"2021-11-23T14:46:52+00:00","author":"admin_fchau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin_fchau","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#article","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/"},"author":{"name":"admin_fchau","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363"},"headline":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C","datePublished":"2021-11-23T14:46:49+00:00","dateModified":"2021-11-23T14:46:52+00:00","mainEntityOfPage":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/"},"wordCount":481,"commentCount":0,"publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","name":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C - ANRS CO22 HEPATHER","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website"},"datePublished":"2021-11-23T14:46:49+00:00","dateModified":"2021-11-23T14:46:52+00:00","breadcrumb":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/"},{"@type":"ListItem","position":2,"name":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C"}]},{"@type":"WebSite","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","name":"ANRS CO22 HEPATHER","description":"","publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization","name":"IPLESP UMRS 1136","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","contentUrl":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","width":464,"height":175,"caption":"IPLESP UMRS 1136"},"image":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363","name":"admin_fchau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","caption":"admin_fchau"},"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_fchau\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/paQKc4-R4","jetpack-related-posts":[{"id":3303,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","url_meta":{"origin":3290,"position":0},"title":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!","author":"admin_fchau","date":"23 novembre 2021","format":false,"excerpt":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l'identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l'h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3204,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/une-communication-large-sur-anrs-co22-hepather-lors-du-congres-francais-de-lassociation-francaise-pour-letude-du-foie-afef-en-octobre-2019\/","url_meta":{"origin":3290,"position":1},"title":"Une communication large sur ANRS CO22 Hepather lors du congr\u00e8s fran\u00e7ais de l\u2019Association Fran\u00e7aise pour l\u2019Etude du Foie (AFEF) en octobre 2019","author":"C\u00e9line Dorival Mouly","date":"9 septembre 2019","format":false,"excerpt":"Diff\u00e9rentes \u00e9tudes issues des donn\u00e9es de la cohorte HEPATHER seront pr\u00e9sent\u00e9s au congr\u00e8s de l\u2019AFEF qui se d\u00e9roule du 2 au 5 octobre 2019 \u00e0 Marseille. \u00a0 3 travaux seront pr\u00e9sent\u00e9s \u00e0 l\u2019oral \u00a0: Le vendredi 4 octobre \u00e0 15h42 Le devenir clinique des patients VHC avec ant\u00e9c\u00e9dent de d\u00e9compensation\u2026","rel":"","context":"Dans "Non class\u00e9"","block_context":{"text":"Non class\u00e9","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/non-classe\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3372,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2022-15-travaux-publies-a-partir-des-donnees-de-la-cohorte-hepather\/","url_meta":{"origin":3290,"position":2},"title":"2022. 15 travaux publi\u00e9s \u00e0 partir des donn\u00e9es de la cohorte HEPATHER !","author":"admin_fchau","date":"17 d\u00e9cembre 2022","format":false,"excerpt":"Ces \u00e9tudes apportent des avanc\u00e9es importantes dans la compr\u00e9hension des h\u00e9patites virales B et C et de leurs complications, notamment en mati\u00e8re de d\u00e9pistage pr\u00e9coce, de facteurs de risque et de strat\u00e9gies pr\u00e9ventives.Plusieurs \u00e9tudes r\u00e9alis\u00e9es par l'\u00e9quipe de sciences sociales du SESSTIM (Inserm, Universit\u00e9 Aix Marseille et IRD) ont port\u00e9\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3206,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/7-travaux-issus-de-la-cohorte-seront-presentes-au-congres-americain-de-lamerican-association-for-the-study-of-liver-diseases-aasld-en-novembre-2019\/","url_meta":{"origin":3290,"position":3},"title":"7 travaux issus de la cohorte seront pr\u00e9sent\u00e9s au congr\u00e8s am\u00e9ricain de l\u2019American Association for the Study of Liver Diseases (AASLD) en novembre 2019\u00a0!","author":"C\u00e9line Dorival Mouly","date":"9 septembre 2019","format":false,"excerpt":"Diff\u00e9rentes \u00e9tudes issues des donn\u00e9es de la cohorte HEPATHER seront pr\u00e9sent\u00e9s au congr\u00e8s de l\u2019AASLD qui se d\u00e9roule du 8 au 12 novembre 2019 \u00e0 Boston. \u00a0 1 travail sera pr\u00e9sent\u00e9 \u00e0 l\u2019oral \u00a0: Lors de la session parall\u00e8le 28 le lundi 11 novembre \u00e0 11h30 (Ballroom A) L\u2019impact sur\u2026","rel":"","context":"Dans "Non class\u00e9"","block_context":{"text":"Non class\u00e9","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/non-classe\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3393,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2024-une-annee-de-preparation-et-de-transition-3-publications-par-lequipe-du-sesstim\/","url_meta":{"origin":3290,"position":4},"title":"2024 – une ann\u00e9e de pr\u00e9paration et de transition. 3 publications par l’\u00e9quipe du SESSTIM.","author":"admin_fchau","date":"17 mars 2025","format":false,"excerpt":"L'ann\u00e9e 2024 a \u00e9t\u00e9 marqu\u00e9e par la pr\u00e9paration de la suite de la cohorte HEPATHER dont la date de fin \u00e9tait programm\u00e9e au 31 d\u00e9cembre 2024.Hepat-B proposera de prolonger le suivi des patients atteints d'h\u00e9patite B inclus dans Hepather jusqu'en 2029, avec la r\u00e9alisation de nouvelles collections biologiques. Cette cohorte\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3376,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2023-premiers-travaux-issus-du-chainage-individuel-des-donnees-de-la-cohorte-hepather-avec-le-systeme-national-des-donnees-de-sante-5-publications\/","url_meta":{"origin":3290,"position":5},"title":"2023 – Premiers travaux issus du cha\u00eenage individuel des donn\u00e9es de la cohorte Hepather avec le Syst\u00e8me National des Donn\u00e9es de Sant\u00e9. 5 publications","author":"admin_fchau","date":"17 d\u00e9cembre 2024","format":false,"excerpt":"Le cha\u00eenage avec les donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SDNS) autoris\u00e9 par la commission nationale informatique et libert\u00e9 en 2018 a \u00e9t\u00e9 r\u00e9alis\u00e9 pour plus de 80% des participants de la cohorte qui ont donn\u00e9 leur consentement, \u00e0 partir de la reconstruction du num\u00e9ro d'identification au r\u00e9pertoire\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/comments?post=3290"}],"version-history":[{"count":3,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3290\/revisions"}],"predecessor-version":[{"id":3294,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3290\/revisions\/3294"}],"wp:attachment":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/media?parent=3290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/categories?post=3290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/tags?post=3290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}